Flexion Therapeutics Reports Top-Line Data From Pivotal Phase 2b Clinical Trial for FX006
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Needham & Company Cuts Price Target on Flexion Therapeutics (FLXN) Following Top-Line FX006 Data
September 9, 2015 7:41 AM EDTNeedham & Company reiterated a Buy rating on Flexion Therapeutics (NASDAQ: FLXN), and cut the price target to $28.00 (from $31.00), following top-line data from the first of two pivotal trials evaluating FX006 in osteoarthritis (OA) knee pain.
Analyst Serge Belanger commented, FLXN reported... More
Flexion Therapeutics (FLXN) Announces First Phase 2b of FX006 in OA Knee Pain Missed Primary Endpoint
September 8, 2015 4:07 PM EDTFlexion Therapeutics (NASDAQ: FLXN) reported top-line results from the first of two pivotal clinical trials of its lead drug candidate FX006 in patients with moderate to severe osteoarthritis (OA) knee pain. In this trial, 40 mg of FX006, compared to placebo (saline), demonstrated statistical significance in average pain relief over weeks 1 through 12 (p = 0.0012; 2-sided) and over weeks 1 through 24 (p = 0.0209; 2-sided). At weekly time points, 40 mg of FX006 also demonstrated superiority to placebo in pain relief beginning at week 1, continuing to week 11 and also at week 13 (p... More
